论文部分内容阅读
目的探讨FOLFOX方案与CF方案新辅助化疗对大肠癌患者免疫功能的影响。方法入组83例大肠癌患者,其中观察组43例,行FOLFOX新辅助化疗1个周期,对照组40例,行CF方案新辅助化疗1个周期,化疗结束后1周如Karnofsky评分≥80分则行根治性手术。比较2组患者新辅助化疗前及术后第7天、第14天外周血T细胞亚群免疫及血清IgG水平;同时检测50例正常健康人的免疫功能进行对照。结果 3组患者治疗前T细胞亚群及IgG水平均无显著差异;观察组及对照组患者术后第7天外周血T细胞亚群免疫功能及血清IgG水平均下降,术后第14天均有所恢复,但2组间无显著差异。结论经FOLFOX方案与CF方案新辅助化疗对大肠癌患者免疫功能的影响均基本相同,临床上可根据具体情况针对性选用不同方案进行新辅助化疗。
Objective To investigate the effects of neoadjuvant chemotherapy with FOLFOX regimen and CF regimen on immune function in patients with colorectal cancer. Methods A total of 83 patients with colorectal cancer were enrolled. Among them, 43 patients in the observation group underwent one cycle of neoadjuvant chemotherapy with FOLFOX and 40 patients in the control group. One cycle of neoadjuvant chemotherapy with CF regimen was performed. One week after chemotherapy, such as Karnofsky score ≥ 80 minutes is a radical surgery. The peripheral blood T cell subsets and serum IgG levels were compared before and after neoadjuvant chemotherapy on the 7th day and the 14th day after surgery. The immune function of 50 healthy controls were also compared. Results There was no significant difference in T lymphocyte subsets and IgG levels between the three groups before treatment. In the observation group and the control group, the immune function of peripheral blood T lymphocyte subsets and serum IgG levels decreased on the 7th day after operation. On the 14th day after operation, Some recovery, but no significant difference between the two groups. Conclusion The effects of neoadjuvant chemotherapy with FOLFOX regimen and CF regimen on immune function in patients with colorectal cancer are basically the same. Neoadjuvant chemotherapy can be clinically selected according to the specific circumstances.